Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia

Journal of Clinical Apheresis

Volumn 24, Issue 6, 2009, Pages 241-246

  Stefanutti, Claudia ^a   Vivenzio, Antonio ^a   Di Giacomo, Serafina ^a   Labbadia, Giancarlo ^a   Mazza, Fabio ^a   D'Alessandri, Giovanna ^b   Ferraro, Pietro M ^c   Masala, Cesare ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b ASL 3   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

HCV related cryoglobulinemia; Immunoadsorption apheresis; Immunosuppressive drug therapy

Indexed keywords

ALBUMIN; ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2A; PLASMA PROTEIN; PREDNISONE; RIBAVIRIN;

ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; FEMALE; HEPATITIS C VIRUS; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LEG ULCER; MALE; NEPHRITIS; PARALLEL DESIGN; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SCORING SYSTEM; SJOEGREN SYNDROME; SKIN NECROSIS; SKIN ULCER; SYMPTOMATOLOGY; TREATMENT DURATION; VASCULITIS;

ADULT; AGED; BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED;

EID: 71849091311     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20222     Document Type: Article

References (23)

1. Schott P, Hartmann H, Ramadori G: Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanisms of cryoprecipitation and options of treatment. Histol Histopathol 2001;16:1275-1285 (Review 1).
2. Petersen J. Essential cryoglobulinaemia: a clinical course lasting 25 years. Scand J Haematol 1985;35:501-504. (Pubitemid 16156007)
3. Agnello V. Mixed cryoglobulinemia and hepatitis C virus. Hosp Pract 1995;30:35-42.
4. Weber M, Kohler H, Fries J, Thoenes W, Meyer zum Buschenfelde KH. Rapidly progressive glomerulonephritis in IgA/IgG cryoglobulinemia. Nephron 1985;41:258-261.
5. Ballare M, Bobbio F, Poggi S, Bordin G, Bertoncelli MC, Catania E, Monteverde A. A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13:S201-S203.
6. Geltner D, Kohn RW, Gorevic P, Franklin EC. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981;24: 1121-1127. (Pubitemid 11057338)
7. Tavoni A, Mosca M, Ferri C, Moriconi L, La Civita L, Lombardini F, Bombardieri S: Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13:S191-S195 (Review). (Pubitemid 26127959)
8. Delaney VB, Fraley DS, Segal DP, Bruns FJ. Plasmapheresis as sole therapy in a patient with essential mixed cryoglobulinemia. Am J Kidney Dis 1984;4:75-77.
9. Berkman EM, Orlin JB. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 1980;20:171-178.
10. Dominguez JH, Sha E. Apheresis in cryoglobulinemia complicating hepatitis C and in other renal diseases. Ther Apher 2002;6:69-76 (Review). (Pubitemid 34218730)
11. Braun N, Bosch T. Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 2000;9:2017-2038. (Pubitemid 30686927)
12. Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl 1998;64:S61-S65 (Review).
13. Nakaji S. Current topics on immunoadsorption therapy. Ther Apher 2001;5:301-305.
14. Corvetta A, Marchegiani G, Salvi A, Chirelli PA, Danieli G. Immune complexes and complement profile in essential mixed cryoglobulinemia before and after plasma exchange. Int J Artif Organs 1983;6:65-68.
15. Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenstrom's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher 1999;3:8-19 (Review).
16. Ohshima T, Sawada K, Tanaka J, Zborowski M, Koo AP, Malchesky PS. Do humoral factors removed by plasmapheresis suppress the cellular immune system in cryoglobulinemia? ASAIO Trans 1991;37:M431-M433.
17. Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Gendreau RM, Harris ER, Matteson EL, Roth SH, Schumacher HR, Weisman MH, Furst DE. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999;42:2153-2159. (Pubitemid 30263599)
18. Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, Kawakami M, Nakamura H, Yabuki T, Kutsuki H. Evaluation of adsorption selectivity dextran sulfate bound cellulose beads for the removal of anti-DNA antibodies. Ther Apher 1999;3:75-80. (Pubitemid 29133875)
19. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-365. (Pubitemid 34136572)
20. Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl 1998;64:S61-S65.
21. Lewis EJ. Plasmapheresis in collagen vascular diseases. Ther Apher 1999;3:172-177.
22. Russo GE, Caramiello MS, Vitaliano E, De Marco CM, Pennacchia M, Giusti S, Vannini F, Mannini L, Avanzi G. Haemorheological changes in mixed cryoglobulinaemia during apheresis treatment. Transfus Sci 1996;17:499-503. (Pubitemid 27296567)
23. Stefanutti C, Di Giacomo S, Mareri M, De Lorenzo F, D'alessandri G, Angelico F, Bucci A, Musca A, Mammarella A. Immunoadsorption apheresis (Selesorb©) in the treatment of chronic hepatitis C virus (HCV)- related type 2 mixed cryglobulinemia. Transfus Apher Sci 2003;28:207-214.